A REVIEW OF ANTIMICROBIAL THERAPY IN PNEUMONIA PATIENTS WITH AUGMENTED RENAL CLEARANCE
Main Article Content
Abstract
Augmented renal clearance (ARC) has been relevant among hospitalized patients with pneumonia at the intensive care unit. Standard doses of antibiotics may be inappropriate in those patients due to the lower serum concentration leading to suboptimal treatment, which prolongs the length of stay in hospital and promotes the risk of antibiotic resistance. Therefore, evaluating the risk of ARC and adjusting the dosing regimen would be necessary for patients with ARC. Antimicrobial agents recently recommended for critical pneumonia include carbapenem, fluoroquinolone, aminoglycoside, vancomycin, and linezolid. Data of these antibiotics dosing regimens has been limited in Vietnam and dependent on population PK/PD models. Consequently, the application of those regimens should be critically considered and followed by therapeutic dose monitoring. Consequently, the application of those regimens should be critically considered and followed by therapeutic dose monitoring. More in-depth researches should be carried out to optimize the outcome treatments in this specific population.
Keywords
Augmented renal clearance, pneumonia, antibiotic, population PK/PD model
Article Details
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
References
2. Barrasa H, Soraluce A, Usón E, and et al. (2020), Impact of augmented renal clearance on the pharmacokinetics of linezolid: Advantages of continuous infusion from a pharmacokinetic/pharmacodynamic perspective. Int J Infect Dis. 93, pp.329-338.
3. Carrié C, Chadefaux G, Sauvage N, and et al. (2019), Increased β-Lactams dosing regimens improve clinical outcome in critically ill patients with augmented renal clearance treated for a first episode of hospital or ventilator-acquired pneumonia: A before and after study. Crit Care. 2019 Nov 27;23(1), pp.379.
4. Chen IH, Nicolau DP. (2020), Augmented Renal Clearance and How to Augment Antibiotic Dosing. Antibiotics, 9, pp.393.
5. Duong A, Simard C, Wang YL, and et al. (2021), Aminoglycosides in the Intensive Care Unit: What Is New in Population PK Modeling?. Antibiotics (Basel),10(5), pp.507.
6. Gieling EM, Wallenburg E, Frenzel T, et al (2020). Higher Dosage of Ciprofloxacin Necessary in Critically Ill Patients: A New Dosing Algorithm Based on Renal Function and Pathogen Susceptibility. Clin Pharmacol Ther, 108(4), pp.770-774.
7. Kuti JL. (2016), Optimizing antimicrobial pharmacodynamics: A guide for your stewardship program. Revista Médica Clínica Las Condes, 27(5), pp.615–624.
8. Maguigan KL, Al-Shaer MH, Peloquin CA (2021). Beta-Lactams Dosing in Critically Ill Patients with Gram-Negative Bacterial Infections: A PK/PD Approach. Antibiotics,10, pp.1154.
9. Minichmayr IK, Roberts JA, Frey OR, and et al (2018). Development of a dosing nomogram for continuous-infusion meropenem in critically ill patients based on a validated population pharmacokinetic model. J Antimicrob Chemother, 73(5), pp.1330-1339.
10. Moniz P, Coelho L, Póvoa P (2021). Antimicrobial Stewardship in the Intensive Care Unit: The Role of Biomarkers, Pharmacokinetics, and Pharmacodynamics. Adv Ther, 38(1), pp.164-179.
11. Roberts JA et al (2016). Does critical illness change levofloxacin pharmacokinetics? Antimicrob. Agents Chemother, 60, pp.1459–1463.
12. Tomasa Irriguible TM (2018). Augmented renal clearance: Much more is better? Med Intensiva (Engl Ed), 42(8), pp.500-503.
13. Udy AA, Dulhunty JM, Roberts JA et al (2017). Association between augmented renal clearance and clinical outcomes in patients receiving β-lactam antibiotic therapy by continuous or intermittent infusion: A nested cohort study of the BLING-II randomised, placebo-controlled, clinical trial. Int J Antimicrob Agents, 49(5), pp.624-630.
14. Udy AA, Roberts JA, Boots RJ, and et al. (2010), Augmented renal clearance: Implications for antibacterial dosing in the critically ill. Clin Pharmacokinet, 49(1), pp.1-16.
15. Zaric RZ, Milovanovic J, Rosic N, and et al. (2018), Pharmacokinetics of Vancomycin in Patients with Different Renal Function Levels. Open Med (Wars), 13, pp.512-519.